Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation

Nuclear Medicine and Biology

Volumn 38, Issue 3, 2011, Pages 417-425

  Abbasi, Imtiaz Ahmed ^a  

^a PAKISTAN INSTITUTE OF NUCLEAR SCIENCE AND TECHNOLOGY   (Pakistan)

Author keywords

177Lu; 177Lu labeled MDP; Biodistribution; Bone pain palliation; Skeletal metastases

Indexed keywords

LUTETIUM METHYLENE DIPHOSPHONATE LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BISPHOSPHONIC ACID DERIVATIVE; LUTETIUM; MEDRONIC ACID; RADIOISOTOPE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PURITY; DRUG RETENTION; DRUG STABILITY; DRUG STRUCTURE; DRUG UPTAKE; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; ISOTOPE LABELING; MALE; NONHUMAN; PROCESS OPTIMIZATION; QUALITY CONTROL; RADIOISOTOPE THERAPY; RAT; SCINTILLATION CAMERA; THIN LAYER CHROMATOGRAPHY; ANIMAL; BONE; CHEMISTRY; FEASIBILITY STUDY; METABOLISM; METHODOLOGY; PAIN; PALLIATIVE THERAPY; PH; RADIOCHEMISTRY; SCINTISCANNING; SPRAGUE DAWLEY RAT; TEMPERATURE; TIME;

ANIMALS; BONE AND BONES; DIPHOSPHONATES; FEASIBILITY STUDIES; HYDROGEN-ION CONCENTRATION; LUTETIUM; MALE; PAIN; PALLIATIVE CARE; QUALITY CONTROL; RADIOCHEMISTRY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TEMPERATURE; TIME FACTORS;

EID: 79954415168     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.09.013     Document Type: Article

References (24)

1. Casciato D.A., Chansky H.A. Bone and joint complications. Manual of Clinical Oncology 2000, 601-614. Lippincott Williams Wilkins, Philadelphia, PA. 4th ed. D.A. Casiato, B.B. Lowitz (Eds.).
2. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997, 69:1-18.
3. Janjan N. Bone metastases: approaches to management. Semin Oncol 2001, 28(4 Suppl 11):28-34.
4. LoRusso P. Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol 2001, 28(4 Suppl 11):22-27.
5. Ross J.R., Saunders Y., Edmonds P.M., Patel S., Broadley K.E., Johnston S.R. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. British Medical Journal 2003, 327:1-7.
6. Sandler E.D., Parisi M.T., Hattner R.S. Duration of etidronate effect demonstrated by serial bone scintigraphy. J Nucl Med 1991, 32:1782-1784.
7. Hoskin P.J., Stratford M.R.L., Folkes L.K., Regan J., Yarnold J.R. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet 2000, 355:1428-1429.
8. Subramanian G., McAfee J.G., Blair R.J., Kallfelz F.A., Thomas F.D. Technetium-99m-methylene diphosphonate: a superior agent for skeletal imaging-comparison with other technetium complexes. J Nucl Med 1975, 16:744-755.
9. Domstad P.A., Coupal J.J., Kim E.E., Blake J.S., DeLand F.H. 99mTc-Hydroxymethane diphosphonate: a new bone imaging agent with a low tin content. Radiology 1980, 136:209-211.
10. Love C., Din A.S., Tomas M.B., Kalapparambath T.P., Palestro C.J. Radionuclide bone imaging: an illustrative review. Radiographics 2003, 23:341-358.
11. Mari C., Catafau A., Carrio I. Bone scintigraphy and metabolic disorders. Q J Nucl Med 1999, 43:259-267.
12. Rudd T.G., Allen D.R., Hartnett D.E. Tc-99m methylene diphosphonate versus Tc-99m pyrophosphate: biological and clinical comparison. J Nucl Med 1977, 18:872-876.
13. Val J. Lewington bone-seeking radionuclides for therapy. J Nucl Med 2005, 46(1 Suppl):38S-47S.
14. Hamdy N.A., Papapoulos S.E. The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med 2001, 31:62-68.
15. Neeta P.T., Maria B., Chaitanya R.D. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004, 45(8):1358-1365.
16. Eary J.F., Collins C., Stabin M., Vernon C., Petersdorf S., Baker M., et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993, 34:1031-1036.
17. Collins C., Eary J.F., Donaldson G., Vernon C., Bush N.E., Petersdorf S., et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993, 34:1839-1844.
18. Serafini A.N., Houston S.J., Resche I., Quick D.P., Grund F.M., Ell P.J., et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998, 16:1574-1581.
19. Chakraborty S., Das T., Banerjee S., Sarma H.D., Venkatesh M. Preparation and preliminary biological evaluation of 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints. Nucl Med Commun 2006, 27:661-668.
20. Chang Y., Jeong J., Lee Y.S., Kim Y., Lee D., Chung J.K., et al. Comparison of potential bone pain palliation agents Lu-177-EDTMP and Lu-177-DOTMP. J Nucl Med. 2008, 49(Suppl 1):93.
21. Pillai M.R.A., Chakraborty S., Das T., Venkatesh M., Ramoorthy N. Production logistics of 177Lu for radionuclide therapy. Appl Radiat Isot 2003, 59:109-118.
22. Chakraborty S., Das T., Sarma H.D., Venkatesh M., Banerjee S. Preparation and preliminary studies on 177Lu-labelled hydroxyapatite particles for possible use in the therapy of liver cancer. Nucl Med & Biol 2008, 35:589-597.
23. Firestone R. Table of isotopes 1996, 2112-2114. John Wiley, New York. 8th ed. V.S. Shirly (Ed.).
24. Das T., Chakraborty S., Sarma H.D., Banerjee S. 177Lu-DOTMP: a viable agent for palliative radiotherapy of painful bone metastasis. Radichim Acta 2008, 96:55-61.